T

he European Commission has opened a formal investigation into Aspen Pharma over allegations the drug maker engaged in price gouging for five life-saving cancer medicines, marking the first EC probe into excessive pricing in the pharmaceutical industry.

The move, which was urged last month by consumer advocacy groups in Europe, comes after Italian antitrust authorities last October fined the drug maker $5.5 million for halting supplies of several cancer drugs as a negotiating tactic designed to boost prices by as much as 1,500 percent.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Please stop sending me messages.. Seeing as I am not a member and never will be. Thank you very much and have a nice day!

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.